Clinical trial

The Effects of Empagliflozin on Arterial Wall Characteristics

NCT03639545

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-03-01

PhasePHASE4

Study timeline

Study start (actual)2018-03-01Date precision: day

Registry last updated2018-08-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Vascular Stiffnessunresolved

Hypoglycemic Agentsunresolved

Diabetes Complicationsunresolved

Diabetes Mellitus, Type 1unresolved

Interventions

Empagliflozin 25mgDRUG

MetforminDRUG · verified · RxNorm: metformin

Empagliflozin/MetforminDRUG

Sponsors & collaborators

University Medical Centre Ljubljanalead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03639545 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.